New developments in HBV molecular diagnostics and quantitative serology

Hepatology International

Volumn 2, Issue SUPPL. 1, 2008, Pages

  Bowden, D Scott ^a,b   Thompson, Alex J ^a,c  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Assay; Genotype; HBeAg; HBsAg; Hepatitis B virus; Intrahepatic HBV

Indexed keywords

ADEFOVIR; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; PEGINTERFERON; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; COMBINATION CHEMOTHERAPY; DIAGNOSTIC VALUE; DISEASE COURSE; DNA DETERMINATION; DRUG RESPONSE; GENETIC ANALYSIS; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOASSAY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROLOGY; STANDARDIZATION; TREATMENT DURATION; VALIDITY; VIRUS LOAD; VIRUS REPLICATION;

EID: 55649107672     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9051-8     Document Type: Article

References (46)

1. 1. CJ Chen HI Yang J Su CL Jen SL You SN Lu 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.
2. 2. S Lewin T Walters S Locarnini 2002 Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies Antiviral Res 55 381 96 12206877 10.1016/S0166-3542(02)00071-2 1:CAS:528:DC%2BD38Xms1ygt7c%3D Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res 2002;55:381–96.
3. 3. SR Lewin RM Ribeiro T Walters GK Lau S Bowden S Locarnini 2001 Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed Hepatology 34 1012 20 11679973 10.1053/jhep.2001.28509 1:CAS:528:DC%2BD3MXotlyqsbg%3D Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012–20.
4. 4. ML Funk DM Rosenberg AS Lok 2002 World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants J Viral Hepat 9 52 61 11851903 10.1046/j.1365-2893.2002.00304.x 1:STN:280:DC%2BD387isVGgsA%3D%3D Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52–61.
5. 5. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff 2006 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol 4 936 62 16844425 10.1016/j.cgh.2006.05.016 1:CAS:528:DC%2BD28XptFWmtrg%3D Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936–62.
6. 6. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. Geneva, Switzerland, September 14–16, 2002. J Hepatol 2003;39 Suppl 1:S1–235.
7. 7. YF Liaw N Leung R Guan GK Lau I Merican G McCaughan 2005 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update Liver Int 25 472 89 15910483 10.1111/j.1478-3231.2005.01134.x Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–89.
8. 8. S Locarnini A Hatzakis J Heathcote EB Keeffe TJ Liang D Mutimer 2004 Management of antiviral resistance in patients with chronic hepatitis B Antivir Ther 9 679 93 15535405 1:CAS:528:DC%2BD2cXhtVKqsb%2FJ Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679–93.
9. 9. J Saldanha W Gerlich N Lelie P Dawson K Heermann A Heath 2001 An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques Vox Sang 80 63 71 11339072 10.1046/j.1423-0410.2001.00003.x 1:CAS:528:DC%2BD3MXjvVCjsrk%3D Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63–71.
10. 10. K Kidd-Ljunggren Y Miyakawa AH Kidd 2002 Genetic variability in hepatitis B viruses J Gen Virol 83 1267 80 12029141 1:CAS:528:DC%2BD38XktlGitrk%3D Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267–80.
11. 11. H Norder AM Courouce P Coursaget JM Echevarria SD Lee IK Mushahwar 2004 Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes Intervirology 47 289 309 15564741 10.1159/000080872 Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289–309.
12. 12. H Norder AM Courouce LO Magnius 1994 Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes Virology 198 489 503 8291231 10.1006/viro.1994.1060 1:CAS:528:DyaK2cXitlOhsbk%3D Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489–503.
13. 13. P Arauz-Ruiz H Norder BH Robertson LO Magnius 2002 Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America J Gen Virol 83 2059 73 12124470 1:CAS:528:DC%2BD38XlvVCrsLg%3D Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059–73.
14. 14. L Stuyver S Gendt De C Geyt Van F Zoulim M Fried RF Schinazi 2000 A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness J Gen Virol 81 67 74 10640543 1:CAS:528:DC%2BD3cXjvVKrsg%3D%3D Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67–74.
15. 15. B Clarke S Bloor 2002 Molecular genotyping of hepatitis B virus J Clin Virol 25 Suppl 3 S41 5 12467776 10.1016/S1386-6532(02)00193-2 Clarke B, Bloor S. Molecular genotyping of hepatitis B virus. J Clin Virol 2002;25 Suppl 3:S41–5.
16. 16. T Guettouche HJ Hnatyszyn 2005 Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes Antivir Ther 10 593 604 16152753 1:CAS:528:DC%2BD2MXhtVOlsLbF Guettouche T, Hnatyszyn HJ. Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes. Antivir Ther 2005;10:593–604.
17. 17. JH Kao 2002 Clinical relevance of hepatitis B viral genotypes: a case of deja vu? J Gastroenterol Hepatol 17 113 5 11966938 10.1046/j.1440-1746.2002.02623.x Kao JH. Clinical relevance of hepatitis B viral genotypes: a case of deja vu? J Gastroenterol Hepatol 2002;17:113–5.
18. 18. F Sugauchi E Orito T Ichida H Kato H Sakugawa S Kakumu 2002 Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene J Virol 76 5985 92 12021331 10.1128/JVI.76.12.5985-5992.2002 1:CAS:528:DC%2BD38XktlSqsr8%3D Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985–92.
19. 19. AS Lok F Zoulim S Locarnini A Bartholomeusz MG Ghany JM Pawlotsky 2007 Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 254 65 17596850 10.1002/hep.21698 1:CAS:528:DC%2BD2sXosVyltLY%3D Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254–65.
20. 20. T Shaw A Bartholomeusz S Locarnini 2006 HBV drug resistance: mechanisms, detection and interpretation J Hepatol 44 593 606 16455151 10.1016/j.jhep.2006.01.001 1:CAS:528:DC%2BD28XhsFKktrc%3D Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006;44:593–606.
21. 21. M Hussain S Fung E Libbrecht E Sablon C Cursaro P Andreone 2006 Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir J Clin Microbiol 44 1094 7 16517902 10.1128/JCM.44.3.1094-1097.2006 1:CAS:528:DC%2BD28XjsVylu7g%3D Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006;44:1094–7.
22. 22. C Seeger WS Mason 2000 Hepatitis B virus biology Microbiol Mol Biol Rev 64 51 68 10704474 10.1128/MMBR.64.1.51-68.2000 1:CAS:528:DC%2BD3cXitFygsr4%3D Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51–68.
23. 23. A Laras J Koskinas E Dimou A Kostamena SJ Hadziyannis 2006 Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients Hepatology 44 694 702 16941694 10.1002/hep.21299 1:CAS:528:DC%2BD28XhtVeqt7bO Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44:694–702.
24. 24. M Singh A Dicaire AE Wakil C Luscombe SL Sacks 2004 Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR J Virol Methods 118 159 67 15081611 10.1016/j.jviromet.2004.02.006 1:CAS:528:DC%2BD2cXjtFaltbg%3D Singh M, Dicaire A, Wakil AE, Luscombe C, Sacks SL. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR. J Virol Methods 2004;118:159–67.
25. 25. B Werle-Lapostolle S Bowden S Locarnini K Wursthorn J Petersen G Lau 2004 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 1750 8 15188170 10.1053/j.gastro.2004.03.018 1:CAS:528:DC%2BD2cXlsFaqs78%3D Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750–8.
26. 26. DK Wong MF Yuen H Yuan SS Sum CK Hui J Hall 2004 Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients Hepatology 40 727 37 15349913 10.1002/hep.20353 1:CAS:528:DC%2BD2cXot1Ortbs%3D Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727–37.
27. 27. K Wursthorn M Lutgehetmann M Dandri T Volz P Buggisch B Zollner 2006 Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 675 84 16941693 10.1002/hep.21282 1:CAS:528:DC%2BD28XhtVeqt7bM Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675–84.
28. 28. DK Wong MF Yuen VW Ngai J Fung CL Lai 2006 One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels Antivir Ther 11 909 16 17302253 1:CAS:528:DC%2BD28Xhtlajs7rN Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909–16.
29. 29. CK Hui S Bowden K Jackson WY Au DY Fong AK Lie 2005 Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy Blood 105 2616 7 15746088 10.1182/blood-2004-09-3402 1:CAS:528:DC%2BD2MXisFSku78%3D Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005;105:2616–7.
30. 30. JJ Sung ML Wong S Bowden CT Liew AY Hui VW Wong 2005 Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterology 128 1890 7 15940624 10.1053/j.gastro.2005.03.009 1:CAS:528:DC%2BD2MXlvFKlsLc%3D Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890–7.
31. 31. MF Yuen DK Wong SS Sum HJ Yuan JC Yuen AO Chan 2005 Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection Am J Gastroenterol 100 1099 103 15842584 10.1111/j.1572-0241.2005.41530.x 1:CAS:528:DC%2BD2MXkvVSms7c%3D Yuen MF, Wong DK, Sum SS, Yuan HJ, Yuen JC, Chan AO, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005;100:1099–103.
32. 32. M Deguchi N Yamashita M Kagita S Asari Y Iwatani T Tsuchida 2004 Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay J Virol Methods 115 217 22 14667538 10.1016/j.jviromet.2003.10.002 1:CAS:528:DC%2BD3sXps1Grs7w%3D Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217–22.
33. 33. A Rodella C Galli L Terlenghi F Perandin C Bonfanti N Manca 2006 Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B J Clin Virol 37 206 12 16893678 10.1016/j.jcv.2006.06.011 1:CAS:528:DC%2BD28XhtVygt7fN Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006;37:206–12.
34. 34. TT Aye A Bartholomeusz T Shaw S Bowden A Breschkin J McMillan 1997 Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation J Hepatol 26 1148 53 9186847 10.1016/S0168-8278(97)80125-0 1:STN:280:DyaK2szjtVerug%3D%3D Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148–53.
35. 35. F Bernard G Raymond B Willems JP Villeneuve 1997 Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B J Viral Hepat 4 265 72 9278224 10.1046/j.1365-2893.1997.00055.x 1:STN:280:DyaK2svit1CmtA%3D%3D Bernard F, Raymond G, Willems B, Villeneuve JP. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997;4:265–72.
36. 36. RA Heijtink J Kruining P Honkoop MC Kuhns WC Hop AD Osterhaus 1997 Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B J Med Virol 53 282 7 9365897 10.1002/(SICI)1096-9071(199711)53:3<282::AID-JMV18>3.0.CO;2-J 1:STN:280:DyaK1c%2Fjt1Kjsw%3D%3D Heijtink RA, Kruining J, Honkoop P, Kuhns MC, Hop WC, Osterhaus AD, et al. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997;53:282–7.
37. 37. F Bortolotti M Guido S Bartolacci P Cadrobbi C Crivellaro F Noventa 2006 Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study Hepatology 43 556 62 16496323 10.1002/hep.21077 Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556–62.
38. 38. JH Hoofnagle GM Dusheiko LB Seeff EA Jones JG Waggoner ZB Bales 1981 Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis Ann Intern Med 94 744 8 7235415 1:STN:280:DyaL3M3gsFerug%3D%3D Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744–8.
39. 39. M Manno C Camma F Schepis F Bassi R Gelmini F Giannini 2004 Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years Gastroenterology 127 756 63 15362032 10.1053/j.gastro.2004.06.021 Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004;127:756–63.
40. 40. M Fried Y-F Liaw K Luo 2005 Role of baseline and on-treatment quantitative HBeAg levels in predicting response to Peginterferon alfa-2a (40 kD) (Pegasys) monotherapy in a large, multinational trial of patients with chronic hepatitis B Hepatology 42 268A Fried M, Liaw Y-F, Luo K. Role of baseline and on-treatment quantitative HBeAg levels in predicting response to Peginterferon alfa-2a (40 kD) (Pegasys) monotherapy in a large, multinational trial of patients with chronic hepatitis B. Hepatology 2005;42:268A.
41. 41. RA Heijtink HL Janssen WC Hop AD Osterhaus SW Schalm 2000 Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy J Viral Hepat 7 382 6 10971827 10.1046/j.1365-2893.2000.00246.x 1:STN:280:DC%2BD3M%2Fjs12ktQ%3D%3D Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000;7:382–6.
42. 42. NH Park JW Shin JH Park SJ Bang DH Kim KR Joo 2005 Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B J Viral Hepat 12 216 21 15720539 10.1111/j.1365-2893.2005.00602.x 1:STN:280:DC%2BD2M%2Fpt1Cgug%3D%3D Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. J Viral Hepat 2005;12:216–21.
43. 43. R Perrillo L Mimms K Schechtman D Robbins C Campbell 1993 Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing Hepatology 18 1306 12 8244253 1:STN:280:DyaK2c%2FmtlOlsA%3D%3D 10.1002/hep.1840180604 Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993;18:1306–12.
44. 44. JW Shin NH Park SW Jung BC Kim SH Kwon JS Park 2006 Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive World J Gastroenterol 12 6693 8 17075986 1:CAS:528:DC%2BD2sXntVamtL8%3D Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, et al. Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006;12:6693–8.
45. 45. CC Wang CJ Liu MY Lai JH Kao DS Chen 2007 Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients Liver Int 27 235 9 17311619 10.1111/j.1478-3231.2006.01418.x 1:CAS:528:DC%2BD2sXksVOktrg%3D Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. Liver Int 2007;27:235–9.
46. 46. EK Manesis ES Hadziyannis OP Angelopoulou SJ Hadziyannis 2007 Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 73 82 17503750 1:CAS:528:DC%2BD2sXjs1Gnt7w%3D Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007;12:73–82.